Male InfertilityCROSPNCT05383599
Characterization of Sperm Population Following Different Selection Procedures
An observational study of Male Infertility, run by Universitair Ziekenhuis Brussel at 1 site in Belgium.
Trial summary
The present study aims to determine which of the sperm selection techniques used in IVF (In Vitro Fertilization) laboratory leads to selection of the best/healthiest sperm population based on their morpho-functional parameters. Read more about this study
- Who is it for?
- Any age, men only
- Conditions the study is for
- Male Infertility
- How many people
- 50 participants
- Where
- 1 siteBelgium
- Study dates
- 16 Jul 2022to 1 Aug 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Men only
- Child, Adult, Older adult
Study population: Unused raw semen samples after diagnostic tests will be included in the study if they fulfil the inclusion criteria
Who may be able to join
- semen volume ≥1.5ml
- sperm concentration >20 x 106 spermatozoa/ml
- ≥30% progressive motility
Who cannot join
- semen samples processed for immediate or later use in Assisted Reproductive Medicine
Trial locations and contacts
1 site in 1 country.
Belgium1 site, 1 recruiting
- Recruiting
UZ Brussel CRG
Brussels, 1090
Ileana G Mateizel, PhD
About this study
The present study aims to determine which of the sperm selection techniques used in IVF (In Vitro Fertilization) laboratory leads to selection of the best/healthiest sperm population based on their morpho-functional parameters. Different procedures are currently used in our laboratory to select the sperm population that will be used to inseminate the oocytes: Density Gradient Centrifugation (DGC), DGC in combination with Magnetic Activated Sperm Sorting (MACS), and Microfluidic Sperm Sorting (MSS). The sperm cells selected by these techniques will be evaluated for specific morpho-functional features such as, motility, morphological abnormalities, and apoptotic status [phosphatidylserine translocation (early stages of apoptosis)] and DNA (Deoxyribonucleic Acid) fragmentation as an indicator of stages of apoptosis.
Read the detailed description
Different procedures are currently available to select the sperm population that will be used to inseminate the oocytes during Medical Assisted Reproduction (MAR). The selected population should contain fully functional spermatozoa that possess the ability to reach the fertilization site and allow optimal fertilization and embryo development. These abilities are strictly dependent on specific sperm morpho-functional features such as, but not limited to, motility, morphological abnormalities, apoptotic status [phosphatidylserine translocation (early stages of apoptosis)] and DNA fragmentation (later stages of apoptosis), The present study aims to determine which of the sperm selection techniques used in our IVF laboratory lead to selection of the best/healthy sperm population based on their morpho-functional parameters. For this purpose, unused raw semen after routine diagnostic analysis will be split in 3 fractions and will be processed immediately by different sperm preparation methods: 1) DGC, 2) DGC and MACS, and 3) MSS.
The sperm cells selected by each method will be analyzed for morphological and functional parameters.
Initial sperm concentration (×106/ml) will be assessed using a counting chamber.
Sperm motility will be evaluated on 200 spermatozoa under 40× magnifications and the results will be expressed as percentages.
After each selection procedure, concentration and motility will be determined with the use of a Neubauer counting chamber.
Spermatozoa with normal morphology will be checked on smears stained using Diff Quick Staining on dried smears, 200 spermatozoa will be classified as normal/abnormal according to Kruger strict criteria.
Phosphatidylserine (PS) translocation (early apoptotic marker): will be analyzed using fluorescence microscopy following sperm cell suspension incubation with Annexin V-FITC (Fluorescein Isothiocyanate) and propidium iodide (PI). The spermatozoa will be classified as: viable spermatozoa without PS translocation (PI negative/Annexin negative); viable with translocated PS (PI negative/Annexin positive); dead (PI positive/Annexin positive or PI positive/Annexin negative).
DNA fragmentation index (percentage of sperm cells showing DNA fragmentation per number of cells analyzed; DFI) will be analyzed using terminal deoxynucleotidyl-transferase-mediated deoxyuridine triphosphate-fluorescein nick end labeling (TUNEL) assay protocol (commercially available kit "In Situ Cell Death Detection"; Roche Diagnostic). The cleavage of genomic DNA during apoptosis leads to both single-strand breaks (nicks) and double-stranded, low-molecular-weight DNA fragments. These DNA strand breaks can be identified in an enzymatic reaction in two stages: (1) labeling of DNA strand breaks with TdT (Terminal Deoxynucleotidyl Transferase), and (2) incorporation of Fluorescein isothiocyanate (FITC)-dUTP (deoxyuridine triphosphate) into nucleotide polymers. TUNEL-positive sperm stain green and TUNEL-negative samples stain red and it can be directly detected and quantified by fluorescence microscopy. This kit is designed to be a precise, fast, and simple nonradioactive technique to detect and quantify the number apoptotic cells. It is specific as it labels DNA strand breaks generated during apoptosis, which enables the test to discriminate between apoptotic and necrotic cells.
Descriptive statistics will be used to report mean, median and minimum and maxi-mum values for each variable. Exact test for Friedman's test will be used to investigate the presence of differences across the 3 techniques. Exact test for Wilcoxon signed rank test will be used for pairwise comparisons. A Bonferroni correction will be applied to adjust for multiple comparisons. Level of significance is set at p<0.05, 2-tailed. Statistical analysis will be performed by means of STATA 15.1 and SPSS 26.0 (Statistical Package for the Social Sciences). A number of 50 patients will be included in the study.
The results obtained will help to improve the sperm selection process in the IVF laboratory
- Conditions
- Male Infertility
- Medical subject headings
- Infertility, Male
What is being measured
The primary outcome is the main question the study is designed to answer.
DNA Fragmentation Index
percentage of sperm cells with DNA fragmentation out of selected sperm cells
Measured: 1 year
Progressive Motility Index
percentage of sperm cells with progressive motility out of selected sperm cells
Measured: 1 year
Early Apoptosis Index
percentage of early apoptotic sperm cells out of selected sperm cells
Measured: 1 year
Normal Morphology Index
percentage of morphological normal sperm cells out of selected sperm cells
Measured: 1 year
Concentration
number of sperm cells per ml of ejaculated semen sample
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 May 2022
- Study start16 Jul 2022
- Primary completion16 Jan 2023
- Study completion1 Aug 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Male InfertilityStudies of the same condition, open and under way.
- More trials run by Universitair Ziekenhuis BrusselThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Universitair Ziekenhuis Brussel
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ileana Mateizel, Universitair Ziekenhuis Brussel
- Investigators
- Neelke De Munck, Study director, Brussels IVF
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05383599
- Sponsor's protocol ID
- 22114CROSP_IM
- Acronym
- CROSP
- Status last verified
- Feb 2023
- First submitted
- 13 May 2022
- Last updated
- 6 Feb 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Feb 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Characterization of Sperm Population Following Different Selection Procedures
- ClinicalTrials.gov ID
- NCT05383599
- Acronym / sponsor ID
- CROSP / 22114CROSP_IM
- Conditions
- Male Infertility
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Universitair Ziekenhuis BrusselUniversity, hospital or other
- Study start
- 16 Jul 2022 (actual)
- Primary completion
- 16 Jan 2023 (actual)
- Study completion
- 1 Aug 2023 (estimated)
- First posted
- 20 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The present study aims to determine which of the sperm selection techniques used in IVF (In Vitro Fertilization) laboratory leads to selection of the best/healthiest sperm population based on their morpho-functional parameters. Different procedures are currently used in our laboratory to select the sperm population that will be used to inseminate the oocytes: Density Gradient Centrifugation (DGC), DGC in combination with Magnetic Activated Sperm Sorting (MACS), and Microfluidic Sperm Sorting (MSS). The sperm cells selected by these techniques will be evaluated for specific morpho-functional features such as, motility, morphological abnormalities, and apoptotic status [phosphatidylserine translocation (early stages of apoptosis)] and DNA (Deoxyribonucleic Acid) fragmentation as an indicator of stages of apoptosis.
Detailed description
Different procedures are currently available to select the sperm population that will be used to inseminate the oocytes during Medical Assisted Reproduction (MAR). The selected population should contain fully functional spermatozoa that possess the ability to reach the fertilization site and allow optimal fertilization and embryo development. These abilities are strictly dependent on specific sperm morpho-functional features such as, but not limited to, motility, morphological abnormalities, apoptotic status [phosphatidylserine translocation (early stages of apoptosis)] and DNA fragmentation (later stages of apoptosis), The present study aims to determine which of the sperm selection techniques used in our IVF laboratory lead to selection of the best/healthy sperm population based on their morpho-functional parameters. For this purpose, unused raw semen after routine diagnostic analysis will be split in 3 fractions and will be processed immediately by different sperm preparation methods: 1) DGC, 2) DGC and MACS, and 3) MSS.
The sperm cells selected by each method will be analyzed for morphological and functional parameters.
Initial sperm concentration (×106/ml) will be assessed using a counting chamber.
Sperm motility will be evaluated on 200 spermatozoa under 40× magnifications and the results will be expressed as percentages.
After each selection procedure, concentration and motility will be determined with the use of a Neubauer counting chamber.
Spermatozoa with normal morphology will be checked on smears stained using Diff Quick Staining on dried smears, 200 spermatozoa will be classified as normal/abnormal according to Kruger strict criteria.
Phosphatidylserine (PS) translocation (early apoptotic marker): will be analyzed using fluorescence microscopy following sperm cell suspension incubation with Annexin V-FITC (Fluorescein Isothiocyanate) and propidium iodide (PI). The spermatozoa will be classified as: viable spermatozoa without PS translocation (PI negative/Annexin negative); viable with translocated PS (PI negative/Annexin positive); dead (PI positive/Annexin positive or PI positive/Annexin negative).
DNA fragmentation index (percentage of sperm cells showing DNA fragmentation per number of cells analyzed; DFI) will be analyzed using terminal deoxynucleotidyl-transferase-mediated deoxyuridine triphosphate-fluorescein nick end labeling (TUNEL) assay protocol (commercially available kit "In Situ Cell Death Detection"; Roche Diagnostic). The cleavage of genomic DNA during apoptosis leads to both single-strand breaks (nicks) and double-stranded, low-molecular-weight DNA fragments. These DNA strand breaks can be identified in an enzymatic reaction in two stages: (1) labeling of DNA strand breaks with TdT (Terminal Deoxynucleotidyl Transferase), and (2) incorporation of Fluorescein isothiocyanate (FITC)-dUTP (deoxyuridine triphosphate) into nucleotide polymers. TUNEL-positive sperm stain green and TUNEL-negative samples stain red and it can be directly detected and quantified by fluorescence microscopy. This kit is designed to be a precise, fast, and simple nonradioactive technique to detect and quantify the number apoptotic cells. It is specific as it labels DNA strand breaks generated during apoptosis, which enables the test to discriminate between apoptotic and necrotic cells.
Descriptive statistics will be used to report mean, median and minimum and maxi-mum values for each variable. Exact test for Friedman's test will be used to investigate the presence of differences across the 3 techniques. Exact test for Wilcoxon signed rank test will be used for pairwise comparisons. A Bonferroni correction will be applied to adjust for multiple comparisons. Level of significance is set at p<0.05, 2-tailed. Statistical analysis will be performed by means of STATA 15.1 and SPSS 26.0 (Statistical Package for the Social Sciences). A number of 50 patients will be included in the study.
The results obtained will help to improve the sperm selection process in the IVF laboratory
Study design
- Observational model
- Other
- Time perspective
- Prospective
Who may qualify
- Sex
- Male only
- Age groups
- Child, Adult, Older adult
- Study population
- Unused raw semen samples after diagnostic tests will be included in the study if they fulfil the inclusion criteria
Key inclusion criteria (3 listed)
- semen volume ≥1.5ml
- sperm concentration >20 x 106 spermatozoa/ml
- ≥30% progressive motility
Key exclusion criteria (1 listed)
- semen samples processed for immediate or later use in Assisted Reproductive Medicine
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
DNA Fragmentation Index
Time frame: 1 year
percentage of sperm cells with DNA fragmentation out of selected sperm cells
Progressive Motility Index
Time frame: 1 year
percentage of sperm cells with progressive motility out of selected sperm cells
Early Apoptosis Index
Time frame: 1 year
percentage of early apoptotic sperm cells out of selected sperm cells
Normal Morphology Index
Time frame: 1 year
percentage of morphological normal sperm cells out of selected sperm cells
Concentration
Time frame: 1 year
number of sperm cells per ml of ejaculated semen sample
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Feb 2023.
- Individual participant dataSharing planned: No
Related trials for Male Infertility
Not yet recruiting
Sperm, Exposure and Endocrine Disruptors
Fertility, Male Fertility
Not yet recruitingPhase 2
PRECISION-E2: Teverelix in Women With Endometriosis - Pharmacodynamics, Safety and Precision Medicine Correlates
Endometriosis Pelvic, Endometriosis Ovaries
RecruitingObservational study
Inherited Reproductive Disorders
Genetic Disorder, Infertility
Active, not recruitingPhase 1/2
A Novel Aromatase Inhibitor, Leflutrozole, for Treatment of Non-Obstructive Azoospermia
Infertility Due to Azoospermia, Infertility, Male
Active, not recruiting
YO® Smartphone Home Sperm Test Versus Manual Semen Analysis in Egyptian Men
Semen Analysis, Male Infertility
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Neelke De Munck study director
Brussels IVF
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Male Infertility, run by Universitair Ziekenhuis Brussel at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 6 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact ileana mateizel (003224776690, ileana.mateizel@uzbrussel.be), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
DNA Fragmentation Index (time frame: 1 year). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Feb 2023.